Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT01853644
Title Tivozanib in Recurrent, Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Acronym TIVO
Recruitment Completed
Gender female
Phase Phase II
Variant Requirements No
Sponsors Northwestern University
Indications
Therapies
Age Groups: adult
Covered Countries USA


No variant requirements are available.